Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment
AN OPEN-LABEL, PARALLEL-GROUP, PHARMACOKINETIC STUDY OF MULTIPLE INTRAVENOUS DOSES OF AZTREONAM AND AVIBACTAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT AND NORMAL RENAL FUNCTION
Sponsor: Pfizer
Listed as NCT04486625, this PHASE1 trial focuses on Renal Insufficiency and remains completed. Sponsored by Pfizer, it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Aug 2023 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .